【国泰海通:维持康方生物“增持”评级 目标价123.72港元】国泰海通发布研报称,维持康方生物“增持”评级。公司核心产品接连实现临床突破,步入收获期维持2025-2027年收入预测37.28/59.28/78.00亿元,采用PS估值法,给予2025年28XPS,对应目标价123.72港元。

金融界
28 Apr
国泰海通发布研报称,维持康方生物“增持”评级。公司核心产品接连实现临床突破,步入收获期维持2025-2027年收入预测37.28/59.28/78.00亿元,采用PS估值法,给予2025年28XPS,对应目标价123.72港元。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10